Human drug efflux transporter ABCC5 confers acquired resistance to pemetrexed in breast cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Human drug efflux transporter ABCC5 confers acquired resistance to pemetrexed in breast cancer
Authors
Keywords
-
Journal
Cancer Cell International
Volume 21, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-02-25
DOI
10.1186/s12935-021-01842-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- ABCA8-mediated efflux of taurocholic acid contributes to gemcitabine insensitivity in human pancreatic cancer via the S1PR2-ERK pathway
- (2021) Chunmei Yang et al. Cell Death Discovery
- Pharmacogenomics to Predict Tumor Therapy Response: A Focus on ATP-Binding Cassette Transporters and Cytochromes P450
- (2020) Viktor Hlaváč et al. Journal of Personalized Medicine
- Wnt/IL‐1β/IL‐8 autocrine circuitries control chemoresistance in mesothelioma initiating cells by inducing ABCB5
- (2019) Vladan Milosevic et al. INTERNATIONAL JOURNAL OF CANCER
- Exceptional pemetrexed sensitivity can predict therapeutic benefit from subsequent chemotherapy in metastatic non-squamous non-small cell lung cancer
- (2019) Ji Hyun Park et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- What sustains the multidrug resistance phenotype beyond ABC efflux transporters? Looking beyond the tip of the iceberg
- (2019) Teodora Alexa-Stratulat et al. DRUG RESISTANCE UPDATES
- DHFR/TYMS are positive regulators of glioma cell growth and modulate chemo-sensitivity to temozolomide
- (2019) Mengting Zhao et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- High pemetrexed sensitivity of docetaxel-resistant A549 cells is mediated by TP53 status and downregulated thymidylate synthase
- (2017) Wei-Ting Kuo et al. ONCOLOGY REPORTS
- The FOXM1–ABCC5 axis contributes to paclitaxel resistance in nasopharyngeal carcinoma cells
- (2017) Youxiang Hou et al. Cell Death & Disease
- Drug-Resistant Epilepsy: Multiple Hypotheses, Few Answers
- (2017) Fei Tang et al. Frontiers in Neurology
- PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2016) Suresh Senan et al. JOURNAL OF CLINICAL ONCOLOGY
- Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
- (2016) Corey J Langer et al. LANCET ONCOLOGY
- Clinical effect of pemetrexed as the first-line treatment in Chinese patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer
- (2016) Di Ma et al. Thoracic Cancer
- The modulation of ABC transporter-mediated multidrug resistance in cancer: A review of the past decade
- (2015) Rishil J. Kathawala et al. DRUG RESISTANCE UPDATES
- A Systemic Analysis on Pemetrexed in Treating Patients with Breast Cancer
- (2014) Fang Wan et al. Asian Pacific Journal of Cancer Prevention
- Optimization of Peptides That Target Human Thymidylate Synthase to Inhibit Ovarian Cancer Cell Growth
- (2014) Michela Pelà et al. JOURNAL OF MEDICINAL CHEMISTRY
- Association of ABCC2 −24C>T Polymorphism with High-Dose Methotrexate Plasma Concentrations and Toxicities in Childhood Acute Lymphoblastic Leukemia
- (2014) Yan Liu et al. PLoS One
- A randomized phase II non-comparative study of pemetrexed-carboplatin and gemcitabine-vinorelbine in anthracycline- and taxane-pretreated advanced breast cancer patients
- (2013) DINO AMADORI et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- A Phase II Multicenter Study of Two Different Dosages of Pemetrexed Given in Combination With Cyclophosphamide as First-Line Treatment in Patients With Locally Advanced or Metastatic Breast Cancer
- (2012) Christian Dittrich et al. CANCER INVESTIGATION
- Reduced Folate Carrier Independent Internalization of PEGylated Pemetrexed: A Potential Nanomedicinal Approach for Breast Cancer Therapy
- (2012) Mallaredy Vandana et al. MOLECULAR PHARMACEUTICS
- Impact of Abcc2 [Multidrug Resistance-Associated Protein (Mrp) 2], Abcc3 (Mrp3), and Abcg2 (Breast Cancer Resistance Protein) on the Oral Pharmacokinetics of Methotrexate and Its Main Metabolite 7-Hydroxymethotrexate
- (2011) M. L. H. Vlaming et al. DRUG METABOLISM AND DISPOSITION
- Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer
- (2010) Nicholas J. Robert et al. BREAST CANCER RESEARCH AND TREATMENT
- ABCC11/MRP8 confers pemetrexed resistance in lung cancer
- (2010) Takehiro Uemura et al. CANCER SCIENCE
- Drug Efflux Transporter Multidrug Resistance-Associated Protein 5 Affects Sensitivity of Pancreatic Cancer Cell Lines to the Nucleoside Anticancer Drug 5-Fluorouracil
- (2010) P. K. Nambaru et al. DRUG METABOLISM AND DISPOSITION
- The effects of splicing variant of PXR PAR-2 on CYP3A4 and MDR1 mRNA expressions
- (2009) Yan Liu et al. CLINICA CHIMICA ACTA
- 6-mercaptopurine and 9-(2-phosphonyl-methoxyethyl) adenine (PMEA) transport altered by two missense mutations in the drug transporter gene ABCC4
- (2008) Daniel Janke et al. HUMAN MUTATION
- MRP7/ABCC10 expression is a predictive biomarker for the resistance to paclitaxel in non-small cell lung cancer
- (2008) T. Oguri et al. MOLECULAR CANCER THERAPEUTICS
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started